High-Dose Cytarabine in Consolidation Therapy

High-dose cytarabine (HIDAC) is a critical component of consolidation therapy for acute myeloid leukemia (AML) patients, particularly those 60 years and older. The discussion reveals that while three grams per meter squared is a common dosing standard in younger patients, those over 60 often receive a reduced dose of one and a half grams to minimize toxicity without compromising outcomes. Evidence from various studies suggests that higher doses may be beneficial for younger, fitter individuals, but older patients generally tolerate lower doses better, maintaining beneficial consolidation effects. The podcast highlights the lack of direct comparative trials for these dosing strategies, underscoring the need for clinical discretion based on patient age and risk profile.